于氨双唑钠对局部晚期非小细胞肺癌放射增敏作用的疗效观察

目的：探讨甘氨双唑钠（CMNa）对III期肺癌的放射增敏作用及不良反应。方法：采用随机分组的方法将经病理学确诊的Ⅲ期非小细胞肺癌（NSCLC）患者分为实验组（A组，放疗加甘氨双唑钠）及对照组（B组，单纯放疗）。两组放疗方法均一样。A组在放疗同时，加用CMNa（800mg／m^2），每周3次，至疗程结束；B组为单纯放疗，评价两组疗效及观察不良反应。结果：A组的CR＋PR为82．6％（19／23），显著高于B组的52．2％（12／23），P〈0．05，差异有统计学意义。两组的不良反应比较，P〉0．05，差异无统计学意义。结论：甘氨双唑钠对局部晚期非小细胞肺癌有放射增敏作用．可提高有效率（CR＋PR），但不增加不良反应。

Clinical observations of radiosensitivity on NSCLC by CMNa

Objective： To observe the sensitization and adverse reaction of Metronidazol Amino AcidiumNatricum（CMNa） in radiotherapy for m stage non-small cell lung carcinoma（NSCLC）. Methods： Forty-six patients were enrolled into two groups. 23 cases in the test group received eoncurent CMNa, 800 mg/m^2 three times a week, ivgtt, radiotherapy. 23 cases in the control group received radiotherapy alone. Results： The overall response rate （CR＋PR） in the test group was 82.6%. Control group was 52.2%. The difference of overall rate between two groups was statically significant（P〈0.05）. The rate of adverse reaction between the test group and control group was not different（P〉0.05）. Conclusion： CMNa has remarkable sensitization effect on radiotherapy to NSCLC, but not increasing the rate of adverse reaction.